Patients’ concerns regarding biological agents in rheumatology
- 6 June 2018
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 21 (6) , 1219-1226
Abstract
Objective: The potential side effects of biological agents may increase the anxiety levels of patients and influence not only their desire to use these therapies but also their concordance to treatment. This study aimed to determine the level and prevalence of drug‐related concern in patients treated with biological agents and to acquire additional information regarding the related causes.Materials and Methods: A total of 1134 patients who were using biological agents for at least 3 months with a diagnosis of rheumatic diseases were enrolled. General anxiety levels were evaluated using the State‐Trait Anxiety Inventory (STAI).Results: The most common cause for drug‐related concerns was the potential side effects of the drugs (59.5%). Among the potential side effects, cancer risk was the most common cause for concern (40.1%), followed by the risk of tuberculosis activation (30.7%). Anxiety levels were higher in patients who experienced side effects than in other patients, and this difference was statistically significant (P < 0.05). STAI trait and state scores were moderately correlated with anxiety levels related to the drug (P < 0.001).Conclusion: Anxiety related to biological agents may significantly affect the patients’ anxiety levels. Awareness regarding the patients’ concerns and expectations related to the drug is important to ensure drug adherence and concordance to treatment.Keywords
This publication has 29 references indexed in Scilit:
- Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication – “It could give me two heads and I’d still try it!”BMC Musculoskeletal Disorders, 2013
- Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Research & Therapy, 2010
- Improvement in symptoms and signs in the forefoot of patients with rheumatoid arthritis treated with anti‐TNF therapyJournal of Foot and Ankle Research, 2010
- Impact of Age, Sex, Physical Function, Health-related Quality of Life, and Treatment with Adalimumab on Work Status and Work Productivity of Patients with Ankylosing SpondylitisThe Journal of Rheumatology, 2009
- The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2009
- ‘It's magic stuff’: The experiences of patients with ankylosing spondylitis taking anti‐TNF‐α medicationMusculoskeletal Care, 2008
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Management of depression in rheumatoid arthritis: A combined pharmacologic and cognitive‐behavioral approachArthritis Care & Research, 2003
- What do patients want to know: An empirical approach to explanation generation and validationExpert Systems with Applications, 1995
- Effects of stress management on clinical outcomes in rheumatoid arthritisArthritis & Rheumatism, 1995